Dietary ω-3 Fatty Acids Protect Against Vasculopathy in a Transgenic Mouse Model of Sickle Cell Disease
Overview
Authors
Affiliations
The anemia of sickle cell disease is associated with a severe inflammatory vasculopathy and endothelial dysfunction, which leads to painful and life-threatening clinical complications. Growing evidence supports the anti-inflammatory properties of ω-3 fatty acids in clinical models of endothelial dysfunction. Promising but limited studies show potential therapeutic effects of ω-3 fatty acid supplementation in sickle cell disease. Here, we treated humanized healthy and sickle cell mice for 6 weeks with ω-3 fatty acid diet (fish-oil diet). We found that a ω-3 fatty acid diet: (i) normalizes red cell membrane ω-6/ω-3 ratio; (ii) reduces neutrophil count; (iii) decreases endothelial activation by targeting endothelin-1 and (iv) improves left ventricular outflow tract dimensions. In a hypoxia-reoxygenation model of acute vaso-occlusive crisis, a ω-3 fatty acid diet reduced systemic and local inflammation and protected against sickle cell-related end-organ injury. Using isolated aortas from sickle cell mice exposed to hypoxia-reoxygenation, we demonstrated a direct impact of a ω-3 fatty acid diet on vascular activation, inflammation, and anti-oxidant systems. Our data provide the rationale for ω-3 dietary supplementation as a therapeutic intervention to reduce vascular dysfunction in sickle cell disease.
A review on disease modifying pharmacologic therapies for sickle cell disease.
Mahadevia H, Ponvilawan B, Madan U, Sharma P, Qasim H, Shrestha A Ann Hematol. 2025; .
PMID: 39828781 DOI: 10.1007/s00277-025-06216-1.
Gill R, Al-Badr M, AlGhouti M, Mohamed N, Abou-Saleh H, Rahman M Mar Drugs. 2024; 22(6).
PMID: 38921567 PMC: 11204627. DOI: 10.3390/md22060256.
Management of the Sickle Cell Trait: An Opinion by Expert Panel Members.
Pinto V, De Franceschi L, Gianesin B, Gigante A, Graziadei G, Lombardini L J Clin Med. 2023; 12(10).
PMID: 37240547 PMC: 10219090. DOI: 10.3390/jcm12103441.
Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach.
Maule M, Olivieri B, Guarnieri G, De Franceschi L, Martinelli N, Vaia R J Clin Med. 2023; 12(6).
PMID: 36983294 PMC: 10059265. DOI: 10.3390/jcm12062294.
In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell-Related Injury.
Federti E, Matte A, Recchiuti A, Garello F, Ghigo A, El Nemer W Hemasphere. 2023; 7(3):e848.
PMID: 36874380 PMC: 9977487. DOI: 10.1097/HS9.0000000000000848.